Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
| ▸ | PRNP | P04156 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 2/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9590823 | 0.74 | POLB (0.40) | NPSR1ALDH1A1HPGDKDM4EGAA | |
| SCHEMBL12261075 | 0.74 | GSK3B (0.41) | NPSR1ALDH1A1HPGDGSK3BCA2 | |
| SCHEMBL5150537 | 0.73 | TSHR (0.46) | TSHRALDH1A1HPGDKDM4EHSD17B10 | |
| SCHEMBL12261119 | 0.72 | MAPT (0.37) | NPSR1RXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL3239531 | 0.70 | ALDH1A1 (0.47) | TSHRRXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL2808786 | 0.70 | GSK3B (0.50) | TSHRNPSR1RXFP1KDM4EGSK3B | |
| SCHEMBL8083734 | 0.70 | TSHR (0.43) | TSHRRXFP1ALDH1A1HPGDKDM4E | |
| SCHEMBL17479405 | 0.69 | POLB (0.37) | TSHRNPSR1RXFP1PRNPPPARG | |
| SCHEMBL5478750 | 0.69 | TSHR (0.33) | TSHR | |
| SCHEMBL5478740 | 0.69 | TSHR (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1200445-B1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI CHEM PHARM (IT) | 2003-09-17 | — | — | EP | disclosed |
| US-20020193381-A1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-12-19 | — | — | US | disclosed |
| US-20020183290-A1 | Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY | 2002-12-05 | — | — | US | disclosed |
| US-6486163-B1 | Thienopyranecarboxamide derivatives | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-11-26 | — | — | US | disclosed |
| WO-2002060534-A2 | SELECTIVE ALPHA 1 ANTAGONISTS A + D | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2002-08-08 | — | — | WO | disclosed |
| US-6387909-B1 | VISION DEFECTS; BENIGN PROSTATIC HYPERPLASIA | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-05-14 | — | — | US | disclosed |
| EP-1200445-A1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. (IT) | 2002-05-02 | — | — | EP | disclosed |
| US-6306861-B1 | ANTISPASMODIC AGENTS AND TREATMENT OF INCONSTANCE | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2001-10-23 | — | — | US | disclosed |
| WO-2001009140-A1 | THIENOPYRANECARBOXAMIDE DERIVATIVES | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA (IT) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183290-A1 | Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor | ADRB1, ADRA1D, ADRA1B | TSHR 669/4885NPSR1 170/4885RXFP1 18/4885 |
| US-20020193381-A1 | Thienopyranecarboxamide derivatives | ADRA1D, ADRB3, OPRD1 | TSHR 444/4885NPSR1 150/4885RXFP1 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.